The allegations against Celgene were originally brought under the qui tam, or whistle-blower, provisions of the False Claims Act. The lawsuit alleged the company violated the federal False Claims Act as well as the laws of 28 states and the District of Columbia by submitting false claims to Medicare and Medicaid programs for the cancer drugs it promoted for off-label uses.
The whistle-blower claimed Celgene promoted the two drugs — Thalomid and Revlimid — using false and misleading statements and paid kickbacks to physicians in exchange for prescribing the drugs, according to the DOJ.
Under the settlement, Celgene will pay $259.3 million to the federal government and an additional $20.7 million to 28 states and the District of Columbia.
More articles on legal and regulatory issues:
Pain Management Group to pay $312k to resolve false billing allegations
Patient stabs University of Nebraska Medical Center employee
Healthcare executive gets nearly 10 years in prison for $56.5M fraud scheme
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
